Youhong Yang - Search Results

Year	Number of Results
2007	1
2010	2
2011	2
2012	1
2013	5
2014	3
2015	7
2016	3
2017	7
2018	3
2019	10
2020	6
2021	5
2022	11
2023	11
2024	5

1

APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis.

You H, Ma X, Efe C, Wang G, Jeong SH, Abe K, Duan W, Chen S, Kong Y, Zhang D, Wei L, Wang FS, Lin HC, Yang JM, Tanwandee T, Gani RA, Payawal DA, Sharma BC, Hou J, Yokosuka O, Dokmeci AK, Crawford D, Kao JH, Piratvisuth T, Suh DJ, Lesmana LA, Sollano J, Lau G, Sarin SK, Omata M, Tanaka A, Jia J. You H, et al. Hepatol Int. 2022 Feb;16(1):1-23. doi: 10.1007/s12072-021-10276-6. Epub 2022 Feb 4. Hepatol Int. 2022. PMID: 35119627 Free PMC article. No abstract available.

2

Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver Fibrosis.

Chen W, Yang A, Jia J, Popov YV, Schuppan D, You H. Chen W, et al. Among authors: you h. Hepatology. 2020 Aug;72(2):729-741. doi: 10.1002/hep.31236. Hepatology. 2020. PMID: 32176358 Review.

3

Fibroblast Activation Protein Activates Macrophages and Promotes Parenchymal Liver Inflammation and Fibrosis.

Yang AT, Kim YO, Yan XZ, Abe H, Aslam M, Park KS, Zhao XY, Jia JD, Klein T, You H, Schuppan D. Yang AT, et al. Among authors: you h. Cell Mol Gastroenterol Hepatol. 2023;15(4):841-867. doi: 10.1016/j.jcmgh.2022.12.005. Epub 2022 Dec 13. Cell Mol Gastroenterol Hepatol. 2023. PMID: 36521660 Free PMC article.

4

Matrisome gene-based subclassification of patients with liver fibrosis identifies clinical and molecular heterogeneities.

Chen W, Sun Y, Chen S, Ge X, Zhang W, Zhang N, Wu X, Song Z, Han H, Desert R, Yan X, Yang A, Das S, Athavale D, Nieto N, You H. Chen W, et al. Among authors: you h. Hepatology. 2023 Oct 1;78(4):1118-1132. doi: 10.1097/HEP.0000000000000423. Epub 2023 Apr 27. Hepatology. 2023. PMID: 37098756 Free PMC article.

5

ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trial.

Hu Y, Li H, Zhang H, Chen X, Chen J, Xu Z, You H, Dong R, Peng Y, Li J, Li X, Wu D, Zhang L, Cao D, Jin H, Qiu D, Yang A, Lou J, Zhu X, Niu J, Ding Y. Hu Y, et al. Among authors: you h. Nat Commun. 2023 Oct 12;14(1):6409. doi: 10.1038/s41467-023-42162-0. Nat Commun. 2023. PMID: 37828034 Free PMC article. Clinical Trial.

6

The utility of P-I-R classification in predicting the on-treatment histological and clinical outcomes of patients with hepatitis B and advanced liver fibrosis.

Chang X, Lv C, Wang B, Wang J, Song Z, An L, Chen S, Chen Y, Shang Q, Yu Z, Tan L, Li Q, Liu H, Jiang L, Xiao G, Chen L, Lu W, Hu X, Dong Z, Chen Y, Sun Y, Wang X, Li Z, Chen D, You H, Jia J, Yang Y. Chang X, et al. Among authors: you h. Hepatology. 2024 Feb 1;79(2):425-437. doi: 10.1097/HEP.0000000000000563. Epub 2023 Aug 23. Hepatology. 2024. PMID: 37611260 Free PMC article. Clinical Trial.

7

Histological assessment based on liver biopsy: the value and challenges in NASH drug development.

Tong XF, Wang QY, Zhao XY, Sun YM, Wu XN, Yang LL, Lu ZZ, Ou XJ, Jia JD, You H. Tong XF, et al. Among authors: you h. Acta Pharmacol Sin. 2022 May;43(5):1200-1209. doi: 10.1038/s41401-022-00874-x. Epub 2022 Feb 14. Acta Pharmacol Sin. 2022. PMID: 35165400 Free PMC article. Review.

8

Targeting thrombospondin-2 retards liver fibrosis by inhibiting TLR4-FAK/TGF-β signaling.

Zhang N, Wu X, Zhang W, Sun Y, Yan X, Xu A, Han Q, Yang A, You H, Chen W. Zhang N, et al. Among authors: you h. JHEP Rep. 2024 Jan 24;6(3):101014. doi: 10.1016/j.jhepr.2024.101014. eCollection 2024 Mar. JHEP Rep. 2024. PMID: 38379585 Free PMC article.

9

Cerebral Ischemia/Reperfusion Injury and Pharmacologic Preconditioning as a Means to Reduce Stroke-induced Inflammation and Damage.

Yang H, Qi C, Su F, Shan W, Guo A, Wu J, Wang Y, You H, Wang Q. Yang H, et al. Among authors: you h. Neurochem Res. 2022 Dec;47(12):3598-3614. doi: 10.1007/s11064-022-03789-5. Epub 2022 Nov 3. Neurochem Res. 2022. PMID: 36327016 Review.

10

Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients.

Wu X, Xu X, Zhou J, Sun Y, Ding H, Xie W, Chen G, Ma A, Piao H, Wang B, Chen S, Meng T, Ou X, Yang HI, Jia J, Kong Y, You H. Wu X, et al. Among authors: you h. Clin Mol Hepatol. 2023 Jul;29(3):747-762. doi: 10.3350/cmh.2023.0121. Epub 2023 May 10. Clin Mol Hepatol. 2023. PMID: 37165622 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

72 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Results by year